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Abstract
AIM
To assess the cleansing efficacy and safety of a new 
Colon capsule endoscopy (CCE) bowel preparation 
regimen.
METHODS
This was a multicenter, prospective, randomized, 
controlled study comparing two CCE regimens. Subjects 
were asymptomatic and average risk for colorectal cancer. 
The second generation CCE system (PillCam® COLON 
2; Medtronic, Yoqneam, Israel) was utilized. Preparation 
regimens differed in the 1st and 2nd boosts with the 
Study regimen using oral sulfate solution (89 mL) with 
diatrizoate meglumine and diatrizoate sodium solution 
(“diatrizoate solution”) (boost 1 = 60 mL, boost 2 = 
30 mL) and the Control regimen oral sulfate solution 
(89 mL) alone. The primary outcome was overall 
and segmental colon cleansing. Secondary outcomes 
included safety, polyp detection, colonic transit, CCE 
completion and capsule excretion ≤ 12 h. 
RESULTS
Both regimens had similar cleansing efficacy for the 
whole colon (Adequate: Study = 75.9%, Control = 
77.3%; P  = 0.88) and individual segments. In the 
Study group, CCE completion was superior (Study 
= 90.9%, Control = 76.9%; P  = 0.048) and colonic 
transit was more often < 40 min (Study = 21.8%, 
Control = 4%; P  = 0.0073). More Study regimen 
subjects experienced adverse events (Study = 19.4%, 
Control = 3.4%; P  = 0.0061), and this difference did 
not appear related to diatrizoate solution. Adverse 
events were primarily gastrointestinal in nature and 
no serious adverse events related either to the bowel 
preparation regimen or the capsule were observed. 
There was a trend toward higher polyp detection with 
the Study regimen, but this did not achieve statistical 
significance for any size category. Mean transit time 
through the entire gastrointestinal tract, from ingestion 
to excretion, was shorter with the Study regimen while 
mean colonic transit times were similar for both study 
groups.
CONCLUSION
A CCE bowel preparation regimen using oral sulfate 
solution and diatrizoate solution as a boost agent is 
effective, safe, and achieved superior CCE completion.
Key words: Bowel preparation; Purgative; Capsule 
endoscopy; Endoscopy; Capsule colonoscopy; Large 
intestine
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Current bowel preparation boost agents for 
colon capsule endoscopy have associated risks and 
contraindications. This paper describes a new boost 
agent comprised of two very low dose hyperosmotic 
agents, oral sodium sulfate and diatrizoate solution, 
which appears to be an acceptable alternative regimen 
for colon capsule endoscopy. 
Kastenberg D, Burch WC, Romeo DP, Kashyap PK, Pound DC, 
Papageorgiou N, Fernández-Urien Sainz I, Sokach CE, Rex DK. 
Multicenter, randomized study to optimize bowel preparation 
for colon capsule endoscopy. World J Gastroenterol 2017; 
23(48): 8615-8625  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i48/8615.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i48.8615
INTRODUCTION
Colon capsule endoscopy (CCE) is a non-invasive 
procedure which effectively visualizes the entire colon. 
While CCE technology has advanced, the preparation 
regimen remains a challenge. Not only is a clean and 
fluid filled colon requisite, but the capsule must reach 
the hemorrhoidal plexus within its 12-h battery life. 
Furthermore, the capsule must dwell for a sufficient 
period of time within the colon as rapid transit (< 40 
min) in combination with sub-optimal cleansing may 
lower the sensitivity for detecting polyps[1].
The CCE preparation regimen before capsule 
ingestion focuses on cleansing the colon, whereas post-
capsule ingestion measures are aimed at propelling 
the capsule through the gastrointestinal (GI) tract and 
providing additional cleansing. A full dose purgative, 
typically polyethylene glycol-electrolyte solution (PEG-
ELS), is administered as a split dose prior to capsule 
ingestion. After capsule ingestion, a pro-kinetic 
medication - in the United States metoclopramide - 
8616 December 28, 2017|Volume 23|Issue 48|WJG|www.wjgnet.com
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may be administered if the capsule does not exit the 
stomach within an hour. Upon entering the duodenum, 
and then typically 3 and 5 h later if the capsule has not 
exited the colon, an agent (“boost”) is administered to 
accelerate capsule transit and augment cleansing. 
Generally the first and second boost consists of a 
hyperosmotic agent and, to date, sodium phosphate 
liquid (NaP) has most commonly been used[2-10]. How-
ever, numerous contraindications to the use of NaP 
makes it a non-viable option in the United States[11,12]. 
As an alternative to NaP, a large prospective CCE 
study used oral sulfate solution (OSS) for the first 177 
mL (6 oz.) and second 89 mL (3 oz.) boost[1]. While 
overall bowel preparation adequacy was acceptable, 
an unexpected limitation of this regimen was a higher 
than expected rate of technically inadequate studies 
due to the combination of rapid colonic transit and 
inadequate colon cleansing.  
Diatrizoate meglumine and diatrizoate sodium 
solution (“diatrizoate solution”) is a hyperosmotic 
agent used in radiologic imaging, and when orally 
administered causes an influx of fluid into the GI 
tract resulting in diarrhea[13]. A small CCE study used 
diatrizoate solution alone as a boost agent and found 
high rates of adequate colon cleansing and CCE 
completion, while rapid colonic transit (< 40 min) was 
rare[14]. A larger study combined diatrizoate solution 
with NaP as a boost agent and observed adequate 
colon cleansing in 83%, and CCE completion in 98%, 
of subjects[15]. 
This study evaluated the efficacy and safety of 
a new CCE preparation regimen that combines low 
dose OSS with diatrizoate solution as a boost agent. 
The study was conducted at six centers in the United 
States. 
MATERIALS AND METHODS
This was a multicenter, prospective, randomized, 
controlled study designed to assess the superiority 
of a new colon cleansing regimen for CCE. Six 
centers (2 academic) participated, and subjects were 
enrolled between 5/18/15 and 9/23/15. Each center 
obtained IRB approval prior to study initiation, and 
this protocol was registered with clinicaltrials.gov (ID# 
NCT02481219).
The second generation CCE system (PillCam® 
COLON 2; Medtronic, Yoqneam, Israel), was used in this 
study. This consists of an ingestible capsule, sensors 
attached to the abdominal wall that receive capsule 
signals, a data recorder, and software (RAPID, version 
8.3) enabling image display and creation of reports. 
The primary outcome was overall and segmental 
colon cleansing. Secondary outcomes included polyp 
detection (≥ 6 mm, ≥ 10 mm, and total), colonic 
transit time, CCE completion (defined as visualization 
of the hemorrhoidal plexus), excretion of capsule 
within 12 h of ingestion, and safety. Colon cleansing 
was assessed using a validated 4-point grading scale 
of excellent, good, fair, and poor for individual colon 
segments and for the overall colon[16]. Adequate 
cleansing was defined as a combination of good and 
excellent.
Subjects
Subjects were asymptomatic and average risk for 
colorectal cancer (CRC), and ranged in age from 50-75 
years. Average risk was defined using the American 
Gastroenterology Association Guidelines on Colorectal 
Cancer Screening[17]. Subjects did not have a personal 
history of CRC or adenoma or inflammatory bowel 
disease, a first degree family member with CRC under 
age 60 or two or more first degree relatives with CRC 
at any age, or a personal or family history of a genetic 
syndrome high risk for CRC. 
Furthermore, subjects were excluded if they had a 
negative colon evaluation within 5 years (colonoscopy, 
CTC, flexible sigmoidoscopy, barium enema, or stool 
testing for blood and/or DNA); a history of GI bleeding, 
heme positive stool, or iron deficiency; a contrain-
dication to capsule technology including dysphagia 
or any swallowing disorder, a cardiac pacemaker or 
implanted electromedical device, anticipation of 
magnetic resonance imaging within 7 d of capsule 
ingestion, or increased risk for capsule retention 
including a suspected or known GI motility disorder, 
bowel obstruction, stricture or fistula; a history of 
renal disease; an allergy or contraindication to any 
component of the study regimens; pregnancy or active 
breast feeding; participation in another investigational 
study within 30 d that may interfere with the subject’s 
safety or ability to participate in this study; a member 
of a vulnerable population (prisoner, intellectually 
challenged, etc.); or a severe medical condition such 
that participation is not appropriate due to increased 
risk, lack of benefit of screening, or survival anticipated 
to be less than 6 mo. 
Study procedure
Subjects underwent a screening visit to assess 
eligibility. Demographic information as well as medical 
and surgical history was obtained, and an assessment 
of pregnancy potential was performed. Subjects of 
childbearing potential underwent a urine pregnancy 
test at the time of screening. During the screening 
visit, if eligibility criteria were satisfied, informed 
consent was obtained and subsequently subjects were 
randomized in a 1:1 ratio to receive the study bowel 
preparation regimen (Study) or the comparator control 
bowel preparation regimen (Control) (see bowel 
preparation regimen section below and Table 1). This 
study utilized randomization blocks using a standard 
envelope procedure. The CCE was performed within 45 
days of the screening visit.  
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boost once the capsule entered the duodenum, and 
a 2nd boost 3 h later if the capsule had not been 
excreted. Study and Control regimens differed in the 
composition of these boosts. For the 1st boost, the 
Study regimen used 89 mL (3 oz.) of OSS (SUPREP
® Braintree Laboratories Inc., Braintree, MA) diluted 
to 237 mL (8 oz.) with water and 59 mL (2 oz.) of 
diatrizoate solution (Gastrografin®, Bracco Diagnostics 
Inc., Monroe Township, NJ, United States) diluted to 
207 mL (7 oz.) with water, and for the 2nd boost 89 mL 
(3 oz.) of OSS diluted to 237 mL (8 oz.) with water 
and 30 mL (1 oz.) of diatrizoate solution diluted to 89 
mL (3 oz.) with water. For both the 1st and 2nd boosts, 
the Control regimen used 89 mL (3 oz.) of OSS diluted 
to 237 mL (8 oz.) with water. Subjects in both study 
arms drank at least 946 mL (32 oz.) of water with the 
first and second boosts. 
Two hours after the 2nd boost, if the capsule had not 
been excreted, subjects in both study arms received a 
3rd boost consisting of a 10 mg bisacodyl suppository. 
Diet was identical for subjects in both study arms. 
Safety
Adverse events were recorded throughout the CCE 
preparation regimen. Subjects were called 5-9 d 
after completion of the capsule procedure to confirm 
capsule excretion and record any additional adverse 
events. Adverse events were classified as serious 
or non-serious. Non-serious adverse events were 
characterized and then classified as mild, moderate, or 
severe. 
Comparison of study and control regimens with historic 
comparators
Preparation adequacy, CCE completion, capsule transit 
times, and polyp detection were compared between the 
study and control regimens and similar regimens used 
in two published CCE studies[1,15].The Study regimen 
was compared to Spada et al[15] as both used the 
combination of diatrizoate solution and a hyperosmotic 
The CCE videos were read remotely by two 
readers who had extensive experience reading CCE 
studies and were unassociated with any study site. 
Video assignment to centralized readers utilized a 1:1 
randomization stratified by bowel preparation group 
to minimize bias using MDT data manager (Medtronic, 
Mansfield, MA, United States). Videos were read within 
3 wk of CCE completion, and no more than 5 videos 
per week were read by a single reader.  
Readers used the aforementioned four-point scale 
to grade cleansing for 5 colon segments - cecum, 
right colon, transverse colon, left colon, and rectum. 
Additionally, readers provided an overall cleansing 
grade for the entire colon.   
For each polyp, the location and size, as determined 
by the longest dimension using a software measuring 
tool, was recorded. The time for the capsule to reach 
the cecum, hepatic and splenic flexures, and exit the 
rectum was also measured using software. The cecum 
and last rectum image was identified by the reader, 
and then the other colon landmarks were identified by 
either the software or the reader.  
The completed report was provided to the primary 
investigator at each enrollment site within 3 months of 
the capsule procedure. Follow-up of capsule findings 
was left to the discretion of the primary investigator at 
each site. 
Bowel preparation regimens
The Study and Control bowel preparation regimens are 
summarized in Table 1. For both regimens, all subjects 
took 4 senna tablets the evening of Day -2, and 2 
L of sulfate-free PEG-ELS (NuLYTELY®, Braintree 
Laboratories Inc., Braintree, MA, United States) the 
night before the capsule procedure and again the next 
morning with completion 45-75 min before capsule 
ingestion. If the capsule remained in the stomach 
more than 1 h, subjects in both study arms took 
metoclopramide 10 mg or erythromycin 250 mg orally.
All subjects (Study and Control) received a 1st 
Table 1  Bowel preparation regimens
Time Study regimen Control regimen
2 d prior ≥ 2400 mL (10 glasses) of liquid during the day; 4 senna tablets 
at bedtime
1 d prior Clear liquid diet all day; 2 L sulfate-free PEG-ELS1 at about 7-9 
pm (one 237 mL-296 mL cup (8-10 oz. cup) every 10-15 min)
Day of capsule procedure
   45-75 min prior to capsule ingestion 2 L sulfate-free PEG-ELS
   1 h after capsule ingestion Optional prokinetics (only if capsule in stomach > 1 h): 10 mg 
metoclopramide or 250 mg erythromycin
   1st boost: After capsule entry into small bowel2 89 mL (3 oz) OSS plus 60 mL diatrizoate solution1 89 mL (3 oz.) OSS
   2nd boost: 3 h after 1st boost, only if capsule not excreted 89 mL (3 oz) OSS plus 30 mL diatrizoate solution1 89 mL (3 oz.) OSS
   3rd boost: 2 h after 2nd boost, only if capsule not excreted 10 mg bisacodyl suppository
   2 h after 3rd boost, or after capsule passes (whichever occurs first) Standard full meal
1Diatrizoate solution = diatrizoate meglumine and diatrizoate sodium solution; 2Clear liquids permitted after ingestion of 1st boost, PEG-ELS: Polyethylene 
glycol-electrolyte solution; OSS: Oral sulfate solution. 
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purgative for the 1st and 2nd boosts. However, instead 
of OSS and diatrizoate solution, Spada et al[15]. used 
NaP in combination with diatrizoate solution [1st boost 
= 40 mL (1.4 oz.) NaP and 50 mL (1.7 oz.) diatrizoate 
solution in 1 L (34 oz.) of water; 2nd boost = 25 mL (0.8 
oz.) NaP and 25 ml (0.8 oz.) diatrizoate solution in 
0.5 L (17 oz.) of water].   
The Control regimen was compared to a CCE 
preparation regimen used by Rex et al[1]. Both 
regimens were similar except for the OSS dose used 
for the 1st boost [Control = 89 mL (3 oz.) diluted to 
237 mL (8 oz.) plus an additional 946 mL (32 oz.) of 
water, Rex et al[1] = 177 mL (6 oz.) diluted to 473 mL 
(16 oz.) plus an additional 946 ml (32 oz.) of water]. 
Similar to the Study and Control regimens, both 
Spada et al[15] and Rex et al[1] administered 4 senna 
tablets two days prior to CCE, split dose 4 L PEG-ELS 
beginning the night prior to CCE, and a prokinetic 
agent if the capsule remained in the stomach for more 
than 1 h. 
Statistical analysis
The statistical methods of this study were reviewed by 
Mathilde Lourd, a biostatistician from Medtronic Inc.
Primary outcome: A sample size of 500 patients 
would provide > 80% power to detect a difference 
between the study groups for overall colon preparation 
adequacy with a two-sided test at a significance 
level of 0.05 (adequacy assumptions: 83% Study, 
71% Control). Chi-square or Fisher’s exact test, as 
appropriate, was performed to compare proportions 
of good and excellent cleansing between the two 
preparation regimens. Non-visualized colon segments 
were not graded for cleansing and not included in the 
colon segment preparation grading analysis. 
Secondary outcomes: Chi-square or Fisher’s exact 
tests were used for analyzing polyp detection (≥ 
6 mm, ≥ 10 mm, and any polyp) in total for the 
whole colon and by colon segment, CCE completion 
rate, adverse events in relation to administration 
of diatrizoate solution, and colon capsule excretion 
within 12 h of ingestion. Colon capsule completion 
was defined as excretion of the capsule within 12 h 
of ingestion and complete visualization of the colon. 
t-tests for continuous variables were performed to 
evaluate the difference between the two preparation 
regimens for capsule transit time by colon segment 
and for the entire colon.  
Plan for interim analyses: Interim analyses were 
planned after each group of 50 subjects until a 
final enrollment of 500. Pre-specified criteria were 
established for measures of performance and safety 
that would allow discontinuation of the trial. These 
included the following: (1) an increased prevalence (> 
10%) of polyps (≥ 6 mm and ≥ 10 mm) in the Study 
group; (2) an increased incidence of adequate (good/
excellent) cleansing (> 12%) for the whole colon in 
the Study group; and (3) adverse events in fewer than 
10% of subjects in the Control group.
RESULTS
Subject flow is summarized in Figure 1. There were 
126 subjects screened and consented, 122 subjects 
met eligibility criteria, and 121 ingested any of the 
preparation and were included in the analyses for 
subject characteristics and safety. After excluding 14 
subjects for protocol deviations, 107 were included in 
the analyses for colon cleansing and polyp detection 
by colonic segment, CCE completion and transit times, 
and comparisons between the Control regimen and 
Rex et al[1]. for colon cleansing by segment. Both study 
groups were similar with regard to age, gender, and 
body mass index (BMI) (Table 2).
After excluding 5 additional subjects with ≥ 1 
unseen colon segment (cecum, ascending, or tran-
sverse), 102 subjects were analyzed for overall colon 
cleansing, polyp detection for the whole colon, and 
comparisons between the Study regimen and Spada 
et al[15] and the Control regimen and Rex et al[1] for 
overall cleansing of the colon. Five additional subjects 
were excluded who had both inadequate (fair or poor) 
overall colon cleansing and colonic transit < 40 min. The 
exclusions for this final group matched Spada et al[15] 
and Rex et al[1] to allow comparisons for polyp detection 
for the whole colon. 
The a priori criteria for early termination of this 
study were met after the first group of 50 subjects. 
Because enrollment was rapid, by the time the 
analyses had been completed and the decision to halt 
the study made, more than 100 subjects were enrolled 
and the results are presented herein.    
Cleansing efficacy
For overall colon cleansing, there was no significant 
Table 2  Subject characteristics
Study regimen, n  = 62 Control regimen, n  =  59 P  value
Age (yr) 55.20 55.10 0.888
Gender (male:female) 45:55 49:51 0.660
BMI (mean) 28.50 28.50 0.978
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difference between the Study and Control regimens 
using the 4-point scale of excellent, good, fair or 
poor (Table 3). Overall adequate cleansing (good and 
excellent combined) of the whole colon was similar for 
both study groups (Adequate: Study = 75.9%, Control 
= 77.3%, p = 0.88). When the 4-point scale was used 
to grade individual colon segments, in no segment was 
there a significant difference between the Study and 
Control regimens for any grade (Supplementary Tables 
1-4).  
Polyp detection
Table 4 summarizes overall polyp detection for both 
study groups. There was a trend toward higher polyp 
detection for the whole colon with the Study regimen, 
although this was not statistically significant for any 
size category. When evaluated by colon segment, 
detection of polyps of all sizes (≥ 6 mm, ≥ 10 mm, 
and any polyp) was not significantly different between 
the Study and Control regimens (Supplementary 
Tables 5-7).  
Capsule colon endoscopy completion and transit
Colon capsule completion and transit times are 
summarized in Table 5. Superior completion of the 
CCE procedure was achieved with the Study regimen 
(Study = 90.9%, Control = 76.9%; p = 0.048). Mean 
transit time through the entire GI tract, from ingestion 
to excretion, was shorter with the Study regimen while 
mean colonic transit times were similar for both study 
groups. Significantly more Study regimen subjects 
experienced capsule transit through the colon in 
less than 40 min (Study = 21.8%; Control = 4%, p 
= 0.007). Five subjects (9%) in the Study regimen 
arm had both inadequate colon cleansing and colonic 
transit < 40 min.
Safety
Adverse events occurred more often in subjects 
receiving the Study regimen [Study = 12 (19.4%), 
Control = 2 (3.4%); p = 0.0061], and these were 
primarily related to bowel preparation [Study = 8 
(12.9%), Control = 1 (1.7%); p = 0.0327] and were 
gastrointestinal in nature (Table 6). The incidence of 
adverse events in Study regimen subjects was similar 
before and after administration of diatrizoate solution 
(before diatrizoate solution = 9.7%, after diatrizoate 
solution = 6.5%; p = 0.4142.) One serious adverse 
event occurred with the Study regimen (sinusitis), and 
this was judged unrelated to the preparation regimen 
or the capsule procedure. All adverse events in the 
Control regimen arm were graded as mild, and there 
was a non-significant trend toward a higher level of 
adverse event severity experienced by Study regimen 
Table 3  Overall colon cleansing assessment
Overall cleansing assessment [95%CI] Study regimen, n  = 55 Control regimen, n  = 52 P value
Adequate1 75.9 [62.4; 86.5] 77.3 [62.2; 88.5] 0.876
Excellent 16.7 [7.9; 29.3] 6.8 [1.4; 18.7] 0.216
Good 59.3 [45.0; 72.4] 70.5 [54.8; 83.2] 0.243
Fair 24.1 [13.5; 37.6] 22.7 [11.5; 37.8] 0.875
Poor 0.0 [0.0; 5.9] 0.0 [0.0; 6.6] --
1Includes both excellent and good cleansing.
Table 4  Polyp detection by size for the whole colon
Polyp size [95%CI] Study regimen, n  = 55 Control regimen, n  = 52 P value
≥ 6 mm   36.4 [23.8; 50.4] 21.3 [10.7; 35.7] 0.096
≥ 10 mm 14.6 [6.5; 26.7] 8.5 [2.4; 20.4] 0.346
Any polyp   58.2 [44.1; 71.3] 46.8 [32.1; 61.9] 0.251
Table 5  Colon capsule endoscopy completion and transit times
Study regimen, n  = 55 Control regimen, n  = 52 P value
CCE completion [95%CI] 90.9 [80.0; 97.0] 76.9 [63.2; 87.5] 0.0482
CCE excretion ≤ 12 h [95%CI] 90.9 [80.0; 97.0] 80.4 [66.9; 90.2] 0.121
GI tract transit - Ingestion to excretion1, mean (SD) [95%CI] 5:54 (6:00) [4:18; 7:30] 9:00 (11:48) [5:36; 12:24] 0.107
Colonic transit time1, mean (SD) [95%CI] 2:12 (1:36) [1:48; 2:42] 2:36 (1:30) [2:06; 3:06] 0.262
Colonic Transit < 40 min [95%CI] 21.8 [11.8; 35.0] 4.0 [0.5; 13.7] 0.0072
1All transit times measured as (h:min); 2Statistically significant. CCE: Colon capsule endoscopy.
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subjects (Table 6). 
Comparisons to historical groups
Study regimen: The Study regimen demonstrated 
no significant difference as compared to Spada et al[15] 
for overall cleansing of whole colon, CCE completion, 
capsule transit through the entire GI tract, and overall 
polyp detection (Table 7). 
Control regimen: The Control and Rex et al[1] 
regimens had similar overall cleansing efficacy for 
the whole colon and for individual colon segments. 
However, the Control regimen had a significantly lower 
rate of completion (Control = 77.6%, Rex et al[1] = 
89%; p = 0.041) and a longer mean colonic transit 
time (Control = 2 h 48 min, Rex et al[1] = 1 h 52 
min; p < 0.001). Polyp detection was not significantly 
Screened subjects
n  = 126
Consented subjects
n  = 126
n  = 4 subjects identified as screen failure 
after obtaining informed consent
Randomized subjects
n  = 122
Study
n  = 62
Control
n  = 60
n  = 1 subject randomized but did not drink 
preparation regimen or swallow capsule
A1
n  = 121
Study
n  = 62
Control
n  = 59
n  = 14 subjects deviated from the 
preparation regimen and/or colon capsule 
procedure(s) as per protocol
B2
n  = 107
Study
n  = 55
Control
n  = 52
C3
n  = 102
Study
n  = 55
Control
n  = 47
n  = 5 subjects with both inadequate (fair or poor) 
cleansing level on overall colon cleansing and with 
colonic transit time < 40 min
D4
n  = 97
Study
n  = 50
Control
n  = 47
n  = 5 subjects with one or more unseen segment(s) 
in cecum/ascending/transverse
Figure 1  Patient flow diagram. 1Group A received any of the CCE preparation regimen = Baseline subject characteristics, safety analysis, comparisons between 
Control regimen and Rex et al[1] and between Study regimen and Spada et al[15]  for colon capsule completion and transit times. 2Group B excluded subjects who 
withdrew before capsule ingestion, had a protocol violation, or experienced technical failure of the capsule = Colon cleansing by segment, CCE completion, CCE 
transit times, polyp detection by colon segment, comparisons between Control regimen and Rex et al[1] for colon cleansing by segment. 3Group C excluded subjects 
listed above (B), and those with non-visualization of the cecum, right colon, or transverse colon = Colon cleansing for whole colon, polyp detection for the whole colon, 
comparisons between the Control regimen and Rex et al[1] and between the Study regimen and Spada et al[15] for overall cleansing of the colon. 4Group D excluded 
subjects listed above (B and C) and those with both inadequate overall colon cleansing and colonic transit time < 40 min = Comparisons between Control regimen and 
Rex et al[1] and Study regimen and Spada et al[15] for whole colon polyp detection.
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different between the two regimens, but there was a 
trend toward higher detection for polyps ≥ 6 mm with 
the Rex et al[1] bowel preparation regimen (Table 8). 
DISCUSSION
A new CCE preparation regimen using OSS + 
diatrizoate as a boost agent did not improve colon 
cleansing as compared to low dose OSS alone. The 
OSS + diatrizoate regimen resulted in more rapid 
transit of the capsule with a trend toward faster transit 
through the entire GI tract, superior CCE completion, 
and more frequent colonic transit less than 40 min. 
There was also a trend toward higher polyp detection 
with OSS + diatrizoate. More subjects receiving OSS 
+ diatrizoate experienced adverse events which were 
primarily related to the bowel regimen and GI in 
nature, but did not appear to be related to diatrizoate 
solution. Patient related factors, not identified in this 
study, may have accounted for this difference in 
adverse events between the Study and Control arms.
The combination of a hyperosmotic colon purgative 
(NaP) and hyperosmotic diatrizoate solution for use 
as a boost agent has previously been shown to be 
effective[15]. The study reported herein evaluated 
the use of OSS as an alternative hyperosmotic colon 
purgative. As a boost agent, OSS + diatrizoate 
performed similarly to the combination of NaP and 
diatrizoate solution with respect to colon cleansing 
adequacy, CCE completion, overall GI transit time, 
and polyp detection. While these results support OSS 
as a boost agent in place of NaP, use of a historical 
comparator is a limitation.  
A large prospective CCE study by Rex et al[1] found 
an unexpectedly high number of capsule studies 
(approximately 10%) could not be evaluated due to a 
combination of inadequate preparation and rapid (< 40 
min) colonic transit. A similar frequency (approximately 
9%) of CCE studies with both inadequate cleansing 
and colon transit < 40 min was observed with the 
Table 6  Adverse events: Frequency and severity by subject
Adverse event Study regimen, n  = 62 Control regimen, n  = 59 P value
Subjects with ≥ 1, n (%) [95%CI] 12 (19.4) [10.4; 31.4] 2 (3.4) [0.4; 11.7] 0.0062
Occurring in > 2% of subjects, n (%) [95%CI]
   Headache 2 (3.2) [0.4; 11.2] 1 (1.7) [0.0; 9.1]
   Nausea 4 (6.5) [1.8; 15.7] 2 (3.4) [0.4; 11.7]
   Vomiting 2 (3.2) [0.2; 38.5] 0 (0) [0.0; 77.6]
Maximum AE severity1, n (%) [95%CI]
   Mild 6 (50) [21.1; 78.9] 2 (100) [22.4; 100.0]
   Moderate 5 (41.7) [15.2; 72.3] 0 (0) [0.0; 77.6] 0.308
   Severe 1 (8.3) [0.2; 38.5] 0 (0) [0.0; 77.6]
1Subjects were counted once according to maximum severity;  2nd Statistically significant.
Table 7  Comparisons between Study regimen and Spada et al [15]: Bowel cleansing, capsule transit, and polyp detection
Parameter Study regimen Spada et al  (4)1 P  value
Adequate preparation-whole colon (% [95%CI]) 75.9 [62.4; 86.5] 78.0[64.0; 88.5] 0.820
CCE completion (% [95%CI]) 90.2 [79.8; 96.3] 96.0 [86.3; 99.5] 0.291
GI transit time2, mean (SD) [95%CI] 6:00 (6:12) [4:24; 7:36] 6:06 (4:48) [4:46; 7:26] 0.925
Polyp detection (% [95%CI])
   ≥ 6 mm 36.0 [22.9; 50.8] 25.0 [13.6; 39.6] 0.233
   ≥ 10 mm 16.0 [7.2; 29.1] 12.5 [4.7; 25.2] 0.619
11st boost = 40 mL sodium phosphate liquid (NaP) and 50 mL diatrizoate solution; 2boost = 25 mL NaP and 25 mL diatrizoate solution; 2All transit times 
measured as (hour: minutes). CCE: Colon capsule endoscopy.
Table 8  Comparisons between Control regimen and Rex et al [1]: Bowel cleansing, capsule completion and transit, and polyp detection
Parameter Control regimen Rex et al  (7)1 P  value
Adequate preparation–whole colon (% [95%CI]) 77.3 [62.2; 88.5] 71.4 [68.1; 74.5] 0.369
CCE completion (% [95%CI]) 77.6 [64.7; 87.5] 89.0 [86.8; 91.0] 0.0413
GI transit time2, mean (SD) [95%CI] 2:48(1:36) [2:18; 3:18] 1:52 (1:40) [1:45; 1:59] < 0.0013
Polyp detection (% [95%CI])
   ≥ 6 mm 21.3 [10.7; 35.7] 31.5 [28.1; 35.1] 0.100
   ≥ 10 mm 8.5 [2.4; 20.4] 11.4 [9.1; 14.0] 0.810
1Used 6 ounces sulfate solution for 1st and 2nd boosts; 2All transit times measured as (hour: minutes); 3Statistically significant. CCE: Colon capsule endoscopy.
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Study regimen. It is unknown whether this trend would 
have continued had enrollment not been terminated 
early. Our Control regimen differed from Rex et al[1] 
only in the OSS dose for the 1st boost [Control = 
89 mL (3 oz.), Rex et al[1] = 177 mL [6 oz.)]. As 
compared to Rex et al[1] boosts comprised of low dose 
OSS alone did slow transit but at a cost of inferior CCE 
completion. These data suggest that while CCE transit 
is too often fast with the Rex et al[1]. regimen, transit 
may be too slow when the 1st and 2nd boost utilize low 
dose OSS alone [1]. Again, these conclusions are limited 
by the use of a historical comparator.
Like colonoscopy, CCE’s effectiveness depends on 
a complete colon exam and adequate preparation. 
Achieving these endpoints with colon capsule is a 
complicated endeavor in that the preparation regimen 
must both cleanse the colon and propel the capsule. 
The lumen must be fluid filled and clear of debris, 
and the capsule needs to traverse the entire colon 
within the limits of its battery life - but not too quickly 
such that findings could be missed. And, just like 
colonoscopy, complete passage through the colon 
and adequate preparation are basic requirements and 
no guarantee that lesions will not be missed. Using 
colonoscopy as the gold standard, a meta-analysis 
showed that the second-generation colon capsule 
utilized in our study had high sensitivity and specificity 
for polyps ≥ 6 mm[18]. The acceptable standards for 
CCE completion and adequate bowel preparation 
remain to be determined, but it is reasonable to 
believe that higher thresholds will translate into better 
outcomes. 
Our study has some additional limitations. While 
enrollment was terminated early using pre-specified 
criteria, outcomes may have varied if full enrollment 
was achieved. While the difference between the Study 
and Control regimens for polyp detection seen after 
the first interim analysis at 50 subjects persisted 
after enrollment closed, this was not the case for 
preparation adequacy or adverse event incidence. 
Colon cleansing was graded per segment and overall 
(primary endpoint), but a preparation receiving an 
overall grade of adequate could have one or more 
individual segments graded as graded as fair or 
poor. Looking to colonoscopy and the Boston Bowel 
Preparation Scale for guidance, a total colon score of 
> 5 is associated with both superior polyp detection 
and high adherence to guidelines for screening and 
surveillance[19]. Yet, individual colon segment scores 
are important, and segments scored < 2 are at greater 
risk for missing polyps[20]. For colon capsule, whether 
an overall cleansing grade of adequate is sufficient 
for quality measures such as polyp detection and 
compliance with interval performance of this procedure 
remains to be determined. Finally, in the study we 
have presented, polyp detection by CCE was not 
confirmed with colonoscopy. However, a meta-analysis 
demonstrating high sensitivity and specificity for 
polyps ≥ 6 mm and ≥ 10 mm with the colon capsule 
utilized for this study provides reassurance regarding 
its accuracy for polyp detection[18]. 
In summary, a CCE preparation regimen combining 
two hyperosmotic agents, OSS and diatrizoate 
solution, as a boost agent was not superior to low 
dose OSS alone for achieving adequate overall 
colon cleansing. The OSS + diatrizoate regimen did 
achieve a high rate of colon capsule completion, was 
associated with trend toward higher polyp detection, 
and performed similarly to a historic comparator boost 
regimen comprised NaP + diatrizoate. The combination 
of inadequate preparation and rapid colonic transit 
seen in some subjects receiving OSS + diatrizoate, 
which may lower the accuracy of CCE, is a potential 
limitation of this regimen and requires additional 
investigation. Future research efforts should continue 
to focus on improving cleansing efficacy and patient 
tolerance while maintaining high rates of colon capsule 
completion. While permitting sufficient capsule dwell 
time in the colon is important to minimize the risk for 
missing lesions, the effect of rapid colonic transit may 
be mitigated with adequate cleansing. 
ARTICLE HIGHLIGHTS
Research background
The technical performance of colon capsule endoscopy (CCE) has made 
great strides, but this technology remains highly dependent on the purgative 
procedure. The ideal capsule preparation would (1) adequately cleanse the 
colon; (2) propel the capsule through the GI tract within its battery life; (3) 
enable sufficient dwell time within the colon for accurate visualization; (4) be 
tolerable and safe; (5) be easily generalizable for the vast majority of patients. 
Each of these areas require improvement, and this study’s significance is that it 
moves this field forward by evaluating a new boost agent.
Research motivation
Tailoring the preparation procedure based on patient characteristics and real-
time capsule feedback (“personalized” medicine) will likely improve CCE 
performance, tolerability, safety, and subsequently acceptance. Technological 
advancements that reliably visualize mucosa obscured by debris, and assist in 
the detection of polyps, would be immensely helpful as well.
Research objectives 
The main objective was to evaluate the efficacy of new boost agent consisting 
of low dose sulfate solution combined with diatrizoate solution (“Study” 
regimen), and comparing this to low dose sulfate solution alone (“Control” 
regimen). We found that colon cleansing was similar between the two regimens, 
but CCE completion and the proportion of subjects in which the capsule passed 
through the colon in less than 40 min were significantly greater with the Study 
regimen. Also observed was numerically greater, not statistically superior, 
polyp detection with the Study regimen. This suggests that it is reasonable 
to incorporate the boost regimen of low dose sulfate solution and diatrizoate 
solution into the preparation procedure for CCE.  
Research methods
This was a multicenter, prospective, randomized, controlled study comparing 
two preparation regimens for CCE at six United States sites, 2 of which were 
academic centers. CCE studies were read centrally by experienced readers 
who were blinded to subject randomization, and a validated cleansing scale for 
CCE was utilized. 
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Research results
The study regimen did not result in superior colon cleansing, but did result in a 
superior rate of CCE completion and higher proportion of studies with colonic 
transit less than 40 min. Increased polyp detection, though not significant, 
was observed in the Study arm suggesting that polyp detection was not 
compromised in this group. However, this study was not powered for polyp 
detection. We also observed a greater incidence of adverse events, primarily 
GI, in the Study group. This observation in the Study group did not appear to 
be related to the boost agent. Progress needs to be made in further improving 
the efficacy of colon cleansing, with the goal for CCE being more closely 
aligned with that established for traditional colonoscopy. Further, simplifying 
the regimen, shortening overall GI transit time, and lessening the incidence 
of adverse events related to the preparation regimen are all worthy of further 
study. 
Research conclusions
Diatrizoate solution augments the performance of sulfate solution to create 
an effective and very low dose hyperosmotic boost agent for CCE. The 
combination of low dose sulfate solution and diatrizoate solution was superior 
to low dose sulfate solution alone with respect to CCE completion and the 
frequency that the capsule traversed the colon in less than 40 minutes. These 
findings, along with a trend toward higher polyp detection with the combination 
Study regimen, support the use of low dose sulfate solution combined with 
diatrizoate solution as a boost agent in place of low dose sulfate solution alone.
Research perspectives
While our findings represent an improvement in the preparation regimen for 
CCE, there is still much progress to be made in this arena. In particular, the 
rate of preparation adequacy needs to increase. Personalized medicine may 
play a role in optimizing the regimen for CCE. Using patient characteristics and 
real time capsule data, individual adjustments might include varying the volume 
of PEG-ELS, utilizing additional agents, adjusting the frequency and timing of 
medication administration, and more.  
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